Phase III study of Kevzara in severely or critically ill COVID-19 patients misses primary endpoint Sep. 1, 2020
BeiGene and Singlomics sign license agreement for SARS-CoV-2-neutralizing antibody drug candidates Sep. 1, 2020
FDA expands EUA for Veklury to include hospitalized patients with mild or moderate COVID-19 Aug. 31, 2020
RSS